BLAINJECTIONINJECTABLEPriority Review
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
TECENTRIQ (atezolizumab) by Roche is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2016.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ (atezolizumab) is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. It is used across multiple cancer indications including non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. The drug works by removing the "off switch" that tumors use to evade immune detection.
$0.029BPart D
PeakPeak lifecycle product with moderate Medicare uptake; teams likely optimizing formulary access and managed care positioning rather than building launch infrastructure.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Started Sep 2026
32 enrolled
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+2 more
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Started Jul 2026
36 enrolled
Extensive-stage Small-cell Lung Cancer
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Started Jul 2026
12 enrolled
OsteosarcomaPulmonary Recurrence of Osteosarcoma
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Started Jun 2026
35 enrolled
Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
Started Jun 2026
550 enrolled
Small Cell Lung Cancer Extensive StageSmall-cell Lung CancerSmall Cell Carcinoma+5 more
Worked on TECENTRIQ at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.